Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

<h4>Background</h4>Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tomoko Yamazaki, Mayumi Mori, Satoko Arai, Ryosuke Tateishi, Masanori Abe, Mihoko Ban, Akemi Nishijima, Maki Maeda, Takeharu Asano, Toshihiro Kai, Kiyohiro Izumino, Jun Takahashi, Kayo Aoyama, Sei Harada, Toru Takebayashi, Toshiaki Gunji, Shin Ohnishi, Shinji Seto, Yukio Yoshida, Yoichi Hiasa, Kazuhiko Koike, Ken-ichi Yamamura, Ken-ichiro Inoue, Toru Miyazaki
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
R
Q
Acceso en línea:https://doaj.org/article/f15596b44d6a4b0887f4b037aafb7f1f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f15596b44d6a4b0887f4b037aafb7f1f
record_format dspace
spelling oai:doaj.org-article:f15596b44d6a4b0887f4b037aafb7f1f2021-11-25T05:57:11ZCirculating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.1932-620310.1371/journal.pone.0109123https://doaj.org/article/f15596b44d6a4b0887f4b037aafb7f1f2014-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0109123https://doaj.org/toc/1932-6203<h4>Background</h4>Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC.<h4>Methods and findings</h4>Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99 ± 1.8 µg/ml in men and 6.06 ± 2.1 µg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis.<h4>Conclusion</h4>AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.Tomoko YamazakiMayumi MoriSatoko AraiRyosuke TateishiMasanori AbeMihoko BanAkemi NishijimaMaki MaedaTakeharu AsanoToshihiro KaiKiyohiro IzuminoJun TakahashiKayo AoyamaSei HaradaToru TakebayashiToshiaki GunjiShin OhnishiShinji SetoYukio YoshidaYoichi HiasaKazuhiko KoikeKen-ichi YamamuraKen-ichiro InoueToru MiyazakiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 10, p e109123 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Tomoko Yamazaki
Mayumi Mori
Satoko Arai
Ryosuke Tateishi
Masanori Abe
Mihoko Ban
Akemi Nishijima
Maki Maeda
Takeharu Asano
Toshihiro Kai
Kiyohiro Izumino
Jun Takahashi
Kayo Aoyama
Sei Harada
Toru Takebayashi
Toshiaki Gunji
Shin Ohnishi
Shinji Seto
Yukio Yoshida
Yoichi Hiasa
Kazuhiko Koike
Ken-ichi Yamamura
Ken-ichiro Inoue
Toru Miyazaki
Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.
description <h4>Background</h4>Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC.<h4>Methods and findings</h4>Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99 ± 1.8 µg/ml in men and 6.06 ± 2.1 µg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis.<h4>Conclusion</h4>AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.
format article
author Tomoko Yamazaki
Mayumi Mori
Satoko Arai
Ryosuke Tateishi
Masanori Abe
Mihoko Ban
Akemi Nishijima
Maki Maeda
Takeharu Asano
Toshihiro Kai
Kiyohiro Izumino
Jun Takahashi
Kayo Aoyama
Sei Harada
Toru Takebayashi
Toshiaki Gunji
Shin Ohnishi
Shinji Seto
Yukio Yoshida
Yoichi Hiasa
Kazuhiko Koike
Ken-ichi Yamamura
Ken-ichiro Inoue
Toru Miyazaki
author_facet Tomoko Yamazaki
Mayumi Mori
Satoko Arai
Ryosuke Tateishi
Masanori Abe
Mihoko Ban
Akemi Nishijima
Maki Maeda
Takeharu Asano
Toshihiro Kai
Kiyohiro Izumino
Jun Takahashi
Kayo Aoyama
Sei Harada
Toru Takebayashi
Toshiaki Gunji
Shin Ohnishi
Shinji Seto
Yukio Yoshida
Yoichi Hiasa
Kazuhiko Koike
Ken-ichi Yamamura
Ken-ichiro Inoue
Toru Miyazaki
author_sort Tomoko Yamazaki
title Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.
title_short Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.
title_full Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.
title_fullStr Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.
title_full_unstemmed Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.
title_sort circulating aim as an indicator of liver damage and hepatocellular carcinoma in humans.
publisher Public Library of Science (PLoS)
publishDate 2014
url https://doaj.org/article/f15596b44d6a4b0887f4b037aafb7f1f
work_keys_str_mv AT tomokoyamazaki circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT mayumimori circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT satokoarai circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT ryosuketateishi circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT masanoriabe circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT mihokoban circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT akeminishijima circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT makimaeda circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT takeharuasano circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT toshihirokai circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT kiyohiroizumino circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT juntakahashi circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT kayoaoyama circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT seiharada circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT torutakebayashi circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT toshiakigunji circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT shinohnishi circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT shinjiseto circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT yukioyoshida circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT yoichihiasa circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT kazuhikokoike circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT kenichiyamamura circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT kenichiroinoue circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
AT torumiyazaki circulatingaimasanindicatorofliverdamageandhepatocellularcarcinomainhumans
_version_ 1718414377580756992